The IASLC Targeted Therapies of Lung Cancer meeting is a dynamic meeting with a long tradition. And while this is the first time it will be delivered as a virtual event, we are looking forward to more than 600 participants to share information about ongoing clinical trials of the newest therapies for lung cancer. Meeting presenters will summarize the data on relevant targets for new therapies and share data on preclinical and early clinical data for each of the drugs directed against these targets catalunyafarm.com/. All sessions will include an extended Live Q&A with presenters and world-renowned panelists.

We hope you will be part of the first TTLC Virtual Meeting.